HELLA GmbH & Co. KGaA

  • WKN: A13SX2
  • ISIN: DE000A13SX22
  • Land: Deutschland

Nachricht vom 14.05.2018 | 18:42

HELLA GmbH & Co. KGaA: HELLA GmbH & Co. KGaA is evaluating strategic options for its wholesale activities and is conducting discussions with potential investors

HELLA GmbH & Co. KGaA / Key word(s): Market Report/Statement
HELLA GmbH & Co. KGaA: HELLA GmbH & Co. KGaA is evaluating strategic options for its wholesale activities and is conducting discussions with potential investors

14-May-2018 / 18:42 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Lippstadt, 14 May 2018 - HELLA GmbH & Co. KGaA is evaluating strategic options for its wholesale activities which are conducted under the roof of "Nordic Forum" and has initiated a corresponding structured auction process. In this context the company is currently conducting discussions with a selection of potential investors. Reports which suggest that HELLA has already taken a decision on the sale of the wholesale business and is close to entering into respective agreements, are incorrect. The HELLA management will take an unprejudiced decision in regard to the wholesale activities after the submission of final bids. Also, contrary to certain media reports, there is currently no preferred bidder.


14-May-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

M1 Kliniken: Geschäftsjahr über den Erwartungen

Mit dem deutlichen Anstieg auf 21 Klinikstandorte (Ende 2016: 13) hat die auf ästhetische Medizin spezialisierte M1 Kliniken AG die Basis für einen Ausbau der Umsatz- und Ertragsbasis gelegt. Hinzu kommt die bereits in Umsetzung befindliche Erschließung weiterer Umsatzströme, wie etwa die Erweiterung der Eigenmarken oder die Abdeckung der ästhetischen Zahnmedizin. Das Kursziel beläuft sich auf 18,50 € und das Rating lautet KAUFEN.

Aktueller Webcast

EQS Group AG

Q3-report 2018

18. Mai 2018

Aktuelle Research-Studie

Original-Research: Valneva SE (von First Berlin Equity Research GmbH): BUY Valneva SE

22. Mai 2018